Clinical trial
A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC
NCT03612154 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC
- Lead sponsor
- National Cancer Center, Korea
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 2, 2019
- Completion date
- December 31, 2023
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nonsmall cell lung cancer